ArticleBMC cardiovascular disorders2015

Cost-effectiveness of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome in Canada (OASIS-5).

Jorge Alfonso Ross Terres et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.